Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder CancerBas W.G. van Rhijn, Theodorus van der Kwast, Tahlita C.M. Zuiverloon et al.|European Urology|2010Cited by 193
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Geert J.L.H. van Leenders et al.|European Urology|2020Cited by 89
Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular MarkersChris H. Bangma, Monique J. Roobol, Stacy Loeb et al.|European Urology|2013Cited by 58
Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancerKimberley Kolijn, Geert J.L.H. van Leenders|Oncotarget|2015Cited by 56
Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classificationsBas W.G. van Rhijn, Theodorus van der Kwast, Mireía Musquera et al.|Modern Pathology|2014Cited by 47